Columbia University

Technology Ventures

Latest News

The consortium aligns four major academic institutions in a unified partnership with the shared goal of creating high-impact research programs to discover new treatments for cancer.
By dynamically adjusting a VR user's field of view, the researchers say they've developed a method to reduce motion sickness without sacrificing a sense of presence.
Columbia Engineering Professor Steven K. Feiner and Ajoy Fernandes MS’16 have developed a method of combating virtual reality (VR) sickness that can be applied to consumer head-worn VR displays, such as the Oculus Rift, HTC Vive, Sony PlayStation VR, and Google Cardboard.
The Rio Olympics do not begin until August, but we already know one thing about the winners—their average age will be around 26, at least for endurance athletes like swimmers and runners.
Scientists from the Center for Radiological Research at Columbia University Medical Center have shown that a narrow wavelength of ultraviolet (UV) light safely killed drug-resistant MRSA bacteria in mice, demonstrating a potentially safe and cost-effective way to reduce surgical site infections.
A new study reports on the results of a randomized clinical trial that looked at whether the antidepressant citalopram would enhance complicated grief treatment psychotherapy, and if citalopram would be efficacious without it.
A single exposure to general anesthesia poses no cognitive risk to healthy children under age 3, a critical time in brain development, according to a multicenter study led by researchers at Columbia University Medical Center and NewYork-Presbyterian/Morgan Stanley Children’s Hospital.
An international observational study led by Columbia University researchers has uncovered widespread differences in the treatment of patients with common chronic diseases, including type 2 diabetes, hypertension, and depression.
Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain tumor in adults. Existing treatments against the disease are very limited in their effectiveness, meaning that in most patients tumors recur within a year.